Publications (1)0 Total impact
-
Article: PHASE II TRIAL OF INTRAVENOUSLY ADMINISTERED AMD3100 (PLERIXAFOR) FOR STEM CELL MOBILIZATION IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING A LENALIDOMIDE BASED INITIAL THERAPY
Biology of Blood and Marrow Transplantation. 18(2):S247-S247.